Cell Marker Expression in HUVE Cells Before or After Treatment With TCM, RTCM Lacking or Containing γIFN, or γIFN Alone
| Antibody . | Specificity . | % Positive Cells . | ||||
|---|---|---|---|---|---|---|
| HUVE . | TCMHUVE . | RTCM-HUVE (−γIFN) . | RTCM-HUVE (+γIFN) . | γIFNHUVE . | ||
| CD34 | Hematopoietic precursors cells, vascular endothelial cells, fibroblasts, smooth muscle cells; monoclonal (Monosan) | 75 ± 5 | 68 ± 12 | 73 ± 8 | 62 ± 2 | 73 ± 10 |
| VE-cadherin | Endothelial cells; monoclonal-150 | 76 ± 9 | 84 ± 8 | 93 ± 1 | 86 ± 5 | 87 ± 3 |
| FVIII-RA | Endothelial cells; monoclonal (Dako) | 61 ± 8 | 13 ± 4 | 28 ± 16 | 27 ± 14 | 18 ± 13 |
| EN-4 | Endothelial cells, platelets, monocytes, granulocytes, B cells; monoclonal (Monosan) | 89 ± 6 | 52 ± 6 | 72 ± 13 | 58 ± 10 | 40 ± 5 |
| VCAM-1 | Activated endothelial cells, monocytes, dendritic cells, myoblasts; monoclonal (Amac) | 11 ± 4 | 42 ± 12 | 55 ± 6 | 42 ± 5 | 45 ± 18 |
| ICAM-1 | Activated endothelial cells, monocytes, T and B cells, dendritic cells, epithelial cells; monoclonal (Amac) | 23 ± 12 | 66 ± 13 | 96 ± 3 | 94 ± 3 | 40 ± 1 |
| ELAM-1 | Activated endothelial cells; monoclonal (Amac) | 2 ± 1 | 54 ± 8 | 65 ± 3 | 53 ± 12 | 30 ± 1 |
| HLA-DR | Activated endothelial cells, B cells, monocytes, macrophages, activated T and NK cells; monoclonal (Dako) | Neg | Neg | Neg | 2 ± 1 | 60 ± 4 |
| Antibody . | Specificity . | % Positive Cells . | ||||
|---|---|---|---|---|---|---|
| HUVE . | TCMHUVE . | RTCM-HUVE (−γIFN) . | RTCM-HUVE (+γIFN) . | γIFNHUVE . | ||
| CD34 | Hematopoietic precursors cells, vascular endothelial cells, fibroblasts, smooth muscle cells; monoclonal (Monosan) | 75 ± 5 | 68 ± 12 | 73 ± 8 | 62 ± 2 | 73 ± 10 |
| VE-cadherin | Endothelial cells; monoclonal-150 | 76 ± 9 | 84 ± 8 | 93 ± 1 | 86 ± 5 | 87 ± 3 |
| FVIII-RA | Endothelial cells; monoclonal (Dako) | 61 ± 8 | 13 ± 4 | 28 ± 16 | 27 ± 14 | 18 ± 13 |
| EN-4 | Endothelial cells, platelets, monocytes, granulocytes, B cells; monoclonal (Monosan) | 89 ± 6 | 52 ± 6 | 72 ± 13 | 58 ± 10 | 40 ± 5 |
| VCAM-1 | Activated endothelial cells, monocytes, dendritic cells, myoblasts; monoclonal (Amac) | 11 ± 4 | 42 ± 12 | 55 ± 6 | 42 ± 5 | 45 ± 18 |
| ICAM-1 | Activated endothelial cells, monocytes, T and B cells, dendritic cells, epithelial cells; monoclonal (Amac) | 23 ± 12 | 66 ± 13 | 96 ± 3 | 94 ± 3 | 40 ± 1 |
| ELAM-1 | Activated endothelial cells; monoclonal (Amac) | 2 ± 1 | 54 ± 8 | 65 ± 3 | 53 ± 12 | 30 ± 1 |
| HLA-DR | Activated endothelial cells, B cells, monocytes, macrophages, activated T and NK cells; monoclonal (Dako) | Neg | Neg | Neg | 2 ± 1 | 60 ± 4 |
Marker expression in untreated HUVE cells or in cells treated with TCM, RTCM in the presence or absence of γIFN (4 U/mL), or γIFN alone (103 U/mL). HUVE cells were cultured for 5 to 6 days and stained by immunohistochemistry as described in Materials and Methods. The results shown are the average of the percentage of positive cells from 4 independent experiments ± standard deviations.
Abbreviations: Neg, negative; NK, natural killer; HUVE, untreated HUVE cells; γIFN-HUVE, γIFN-treated HUVE cells; RTCM-HUVE, HUVE cells treated with RTCM (+γIFN, 4 U/mL) or RTCM (−γIFN); TCM-HUVE, TCM-treated HUVE cells.
Donated by E. Dejana (Institute Mario Negri, Milan, Italy).